Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open Label Extension of Study HGT-HIT-094 Evaluating Long Term Safety and Clinical Outcomes of Intrathecal Idursulfase Administered in Conjunction With Elaprase in Patients With Hunter Syndrome and Cognitive Impairment

Next Previous
Search
Trial Profile

An Open Label Extension of Study HGT-HIT-094 Evaluating Long Term Safety and Clinical Outcomes of Intrathecal Idursulfase Administered in Conjunction With Elaprase in Patients With Hunter Syndrome and Cognitive Impairment

Status: Completed
Phase of Trial: Phase II/III

Latest Information Update: 08 May 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Idursulfase (Primary) ; Idursulfase
  • Indications Cognition disorders; Mucopolysaccharidosis II
  • Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
  • Sponsors Shire; Takeda

    • Most Recent Events

    • 02 May 2024 Status changed from active, no longer recruiting to completed.
    • 04 Apr 2024 Planned End Date changed from 29 Mar 2024 to 30 Apr 2024.
    • 04 Apr 2024 Planned primary completion date changed from 29 Mar 2024 to 30 Apr 2024.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top